An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential.

[1]  D. Perlman,et al.  Using qualitative data, people's perceptions, and the science of decision making to inform policy and improve hepatitis C care for people who use drugs. , 2015, The International journal on drug policy.

[2]  Julio S. G. Montaner,et al.  The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. , 2014, Addiction.

[3]  P. Griffiths,et al.  Increasing complexity in European drug use: Highlights from the EMCDDA’s 2014 European drug report , 2014 .

[4]  D. D. Des Jarlais,et al.  Viral Hepatitis Among Drug Users in Methadone Maintenance: Associated Factors, Vaccination Outcomes, and Interventions , 2014, Journal of addictive diseases.

[5]  B. Edlin,et al.  Can hepatitis C be eradicated in the United States? , 2014, Antiviral research.

[6]  F. Altice,et al.  Strategies for Hepatitis C Testing and Linkage to Care for Vulnerable Populations: Point-of-Care and Standard HCV Testing in a Mobile Medical Clinic , 2014, Journal of Community Health.

[7]  J. Lazarus,et al.  Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention , 2014, PloS one.

[8]  Robert T. Chen,et al.  Estimating the Number of Persons Who Inject Drugs in the United States by Meta-Analysis to Calculate National Rates of HIV and Hepatitis C Virus Infections , 2014, PloS one.

[9]  M. Weinstein,et al.  The Hepatitis C Cascade of Care: Identifying Priorities to Improve Clinical Outcomes , 2014, PloS one.

[10]  T. D'Aunno,et al.  Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study. , 2014, American journal of public health.

[11]  A. Mclellan,et al.  The affordable care act and treatment for "substance use disorders:" implications of ending segregated behavioral healthcare. , 2014, Journal of substance abuse treatment.

[12]  G. Dore,et al.  Can hepatitis C virus infection be eradicated in people who inject drugs? , 2014, Antiviral research.

[13]  Zhong-fu Liu,et al.  Epidemiological Implications of HIV-Hepatitis C Co-Infection in South and Southeast Asia , 2014, Current HIV/AIDS Reports.

[14]  L. Burns.  World Drug Report 2013 By United Nations Office on Drugs and Crime New York: United Nations, 2013ISBN: 978‐92‐1‐056168‐6, 151 pp. Grey literature , 2014 .

[15]  Valerie Purdie-Vaughns,et al.  Intervening within and across levels: a multilevel approach to stigma and public health. , 2014, Social science & medicine.

[16]  Bruce G. Link,et al.  Public attitudes regarding individual and structural discrimination: two sides of the same coin? , 2014, Social science & medicine.

[17]  B. Druss,et al.  State parity laws and access to treatment for substance use disorder in the United States: implications for federal parity legislation. , 2013, JAMA psychiatry.

[18]  D. D. Des Jarlais,et al.  A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. , 2013, American journal of public health.

[19]  M. Hellard,et al.  Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.

[20]  P. Bruggmann,et al.  Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Hahn,et al.  Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  J. Hirsch,et al.  Social science research on HIV in Vietnam: A critical review and future directions , 2013, Global public health.

[23]  R. Bayer,et al.  When grammars collide: Harm reduction, drug detention and the challenges of international policy reform efforts in Vietnam , 2013, Global public health.

[24]  E. Drucker.  Drug Law, Mass Incarceration, and Public Health , 2013 .

[25]  B. Tran.  Willingness to pay for methadone maintenance treatment in Vietnamese epicentres of injection-drug-driven HIV infection. , 2013, Bulletin of the World Health Organization.

[26]  P. Mateu-Gelabert,et al.  Perceptions of drug users regarding Hepatitis C screening and care: a qualitative study , 2013, Harm Reduction Journal.

[27]  Enrique R. Pouget,et al.  Trends in the Population Prevalence of People Who Inject Drugs in US Metropolitan Areas 1992–2007 , 2013, PloS one.

[28]  V. Hope,et al.  Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association , 2013, Epidemiology and Infection.

[29]  J. Frimpong.  Missed opportunities for hepatitis C testing in opioid treatment programs. , 2013, American journal of public health.

[30]  T. Rhodes,et al.  Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors , 2013, Harm Reduction Journal.

[31]  Daren Anderson,et al.  Project ECHO: Replicating a Novel Model to Enhance Access to Hepatitis C Care in a Community Health Center , 2013, Journal of health care for the poor and underserved.

[32]  T. Rhodes,et al.  Taming systems to create enabling environments for HCV treatment: negotiating trust in the drug and alcohol setting. , 2013, Social science & medicine.

[33]  D. D. Des Jarlais,et al.  Socio-demographic factors, health risks and harms associated with early initiation of injection among people who inject drugs in Tallinn, Estonia: evidence from cross-sectional surveys. , 2013, The International journal on drug policy.

[34]  R. Walensky,et al.  The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. , 2013, Drug and alcohol dependence.

[35]  A. Abdul-Quader,et al.  High coverage needle/syringe programs for people who inject drugs in low and middle income countries: a systematic review , 2013, BMC Public Health.

[36]  M. Rottenberg,et al.  Expression of M. tuberculosis-induced suppressor of cytokine signaling (SOCS) 1, SOCS3, FoxP3 and secretion of IL-6 associates with differing clinical severity of tuberculosis , 2013, BMC Infectious Diseases.

[37]  O. Senn,et al.  Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting , 2013, BMC Infectious Diseases.

[38]  K. Mulvey,et al.  Methadone Maintenance Therapy in Vietnam: An Overview and Scaling-Up Plan , 2012, Advances in preventive medicine.

[39]  P. Vickerman,et al.  Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. , 2012, Addiction.

[40]  M. Morrow,et al.  Harm reduction and law enforcement in Vietnam: influences on street policing , 2012, Harm Reduction Journal.

[41]  C. Christiansen,et al.  Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[42]  D. D. Des Jarlais,et al.  Multiple routes of drug administration and HIV risk among injecting drug users. , 2012, Journal of substance abuse treatment.

[43]  T. Tallo,et al.  Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C. , 2012, Central European journal of public health.

[44]  L. White,et al.  Treatment of Hepatitis C as Prevention: A Modeling Case Study in Vietnam , 2012, PloS one.

[45]  R. Gish,et al.  Liver disease in Viet Nam: Screening, surveillance, management and education: A 5‐year plan and call to action , 2012, Journal of gastroenterology and hepatology.

[46]  J. Arnsten,et al.  Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics , 2011, BMC infectious diseases.

[47]  J. Parry,et al.  The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. , 2011, Addiction.

[48]  C. Golin,et al.  A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C Treatment , 2011, The American Journal of Gastroenterology.

[49]  J. Daurès,et al.  Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon-α2a and ribavirin. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[50]  Louisa Degenhardt,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[51]  J. Buck.  The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. , 2011, Health affairs.

[52]  C. Hughes,et al.  Illicit drugs and the media: models of media effects for use in drug policy research. , 2011, Drug and alcohol review.

[53]  D. D. Des Jarlais,et al.  Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs , 2011 .

[54]  M. Kals,et al.  Expanded syringe exchange programs and reduced HIV infection among new injection drug users in Tallinn, Estonia , 2011, BMC public health.

[55]  Sanjeev Arora,et al.  Outcomes of treatment for hepatitis C virus infection by primary care providers. , 2011, The New England journal of medicine.

[56]  M. Montagne.  Drugs and the Media: An Introduction , 2011, Substance use & misuse.

[57]  D. Celentano,et al.  Mortality and HIV transmission among male Vietnamese injection drug users. , 2011, Addiction.

[58]  D. Vlahov,et al.  Changes in blood-borne infection risk among injection drug users. , 2011, The Journal of infectious diseases.

[59]  R. Ahas,et al.  Emergent properties of HIV risk among injection drug users in Tallinn, Estonia: synthesis of individual and neighbourhood-level factors , 2010, Sexually Transmitted Infections.

[60]  M. Clatts,et al.  Prevalence and Incidence of HCV Infection among Vietnam Heroin Users with Recent Onset of Injection , 2010, Journal of Urban Health.

[61]  A. Uusküla,et al.  Should Pharmacists have a Role in Harm Reduction Services for IDUs? A Qualitative Study in Tallinn, Estonia , 2009, Journal of Urban Health.

[62]  T. Rhodes,et al.  Knowledge of HIV serostatus and risk behaviour among injecting drug users in Estonia , 2009, AIDS care.

[63]  T. Rhodes.  Risk environments and drug harms: a social science for harm reduction approach. , 2009, The International journal on drug policy.

[64]  M. Edberg.  Drugging the Poor: Legal and Illegal Drugs and Social Inequality (review) , 2009 .

[65]  D. D. Des Jarlais,et al.  Comparison of injecting drug users who obtain syringes from pharmacies and syringe exchange programs in Tallinn, Estonia , 2009, Harm reduction journal.

[66]  Stuart Taylor.  Outside the outsiders: Media representations of drug use , 2008 .

[67]  A. Kamarulzaman.  Global Epidemiology of Injecting Drug Use and HIV Among People Who Inject Drugs: A Systematic Review , 2008 .

[68]  D. D. Des Jarlais,et al.  Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. , 2008, American journal of epidemiology.

[69]  Carla Treloar,et al.  The social production of hepatitis C risk among injecting drug users: a qualitative synthesis. , 2008, Addiction.

[70]  D. D. Des Jarlais,et al.  Barriers and Facilitators to Undergoing Hepatitis C Virus (HCV) Testing through Drug Treatment Programs , 2008 .

[71]  R. Remien,et al.  Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward , 2008, AIDS.

[72]  S. Basu,et al.  International Monetary Fund Programs and Tuberculosis Outcomes in Post-Communist Countries , 2008, PLoS medicine.

[73]  K. Morrow,et al.  A qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV. , 2008, AIDS patient care and STDs.

[74]  D. D. Des Jarlais,et al.  Reducing HIV infection among new injecting drug users in the China–Vietnam Cross Border Project , 2007, AIDS.

[75]  D. Sylvestre,et al.  Integrating HCV services for drug users: a model to improve engagement and outcomes. , 2007, The International journal on drug policy.

[76]  T. Rhodes,et al.  Global estimates of prevalence of HCV infection among injecting drug users. , 2007, The International journal on drug policy.

[77]  S. Galea,et al.  Stigma, discrimination and the health of illicit drug users. , 2007, Drug and alcohol dependence.

[78]  B. Strom,et al.  Drug Utilization Review , 2007 .

[79]  S. Nash.  Human rights update , 2007 .

[80]  D. D. Des Jarlais,et al.  Harm reduction theory: users' culture, micro-social indigenous harm reduction, and the self-organization and outside-organizing of users' groups. , 2007, The International journal on drug policy.

[81]  J. Kaldor,et al.  High hepatitis C incidence in new injecting drug users: a policy failure? , 2007, Australian and New Zealand journal of public health.

[82]  S. Fraser.  The chronotope of the queue: Methadone maintenance treatment and the production of time, space and subjects , 2006 .

[83]  M. Alter,et al.  The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.

[84]  T. Rhodes,et al.  The social structural production of HIV risk among injecting drug users. , 2005, Social science & medicine.

[85]  J. Moskalewicz,et al.  Drugs in the Postsocialist Transitions of Estonia, Latvia, Lithuania and Poland , 2002, European Addiction Research.

[86]  D. Sylvestre.  Treating hepatitis C in methadone maintenance patients: an interim analysis. , 2002, Drug and alcohol dependence.

[87]  A. Uusküla,et al.  The role of injection drug use in the emergence of Human Immunodeficiency Virus infection in Estonia. , 2002, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[88]  A. Uusküla,et al.  Sexually transmitted infections in Estonia—syndromic management of urethritis in a European country? , 2001, International journal of STD & AIDS.

[89]  K. Seal,et al.  Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? , 2001, The New England journal of medicine.

[90]  Xuân Nam Phạm,et al.  Socioeconomic renovation in Viet Nam : the origin, evolution, and impact of Doi Moi , 2001 .

[91]  D. Vlahov,et al.  The natural history of hepatitis C virus infection: host, viral, and environmental factors. , 2000, JAMA.

[92]  P. Bourgois,et al.  Disciplining Addictions: The Bio-politics of Methadone and Heroin in the United States , 2000, Culture, medicine and psychiatry.

[93]  J. McCarthy,et al.  Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. , 1999, AIDS.

[94]  J. M. Calvo Romero,et al.  Gastric adenocarcinoma and kidney transplantation , 1998 .

[95]  A. Uusküla,et al.  Sexually transmitted diseases in Estonia: past and present , 1997, International journal of STD & AIDS.

[96]  W. Brown.  Economic Transition in Estonia , 1993 .

[97]  Sanjeev Arora,et al.  Innovative Telementoring for Pain Management: Project ECHO Pain , 2014, The Journal of continuing education in the health professions.

[98]  C. Beyrer,et al.  What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. , 2014, The International journal on drug policy.

[99]  J. Havens,et al.  Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. , 2013, American journal of public health.

[100]  Alex Harocopos,et al.  Initiation into prescription opioid misuse amongst young injection drug users. , 2012, The International journal on drug policy.

[101]  C. Treloar,et al.  The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics. , 2012, Social science & medicine.

[102]  G. Reida,et al.  Vietnam moves forward with harm reduction : An assessment of progress , 2010 .

[103]  Nguyen Thi Van Anh,et al.  Understanding HIV and AIDS-related Stigma and Discrimination in Vietnam , 2004 .

[104]  Riina Salupere,et al.  KROONILISE C-HEPATIIDI RAVIJUHEND , 2002 .

[105]  H J Alter,et al.  Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.

[106]  D. Jarlais.  Harm reduction--a framework for incorporating science into drug policy. , 1995 .

[107]  S. Friedman,et al.  Harm reduction: a public health response to the AIDS epidemic among injecting drug users. , 1993, Annual review of public health.

[108]  H. Joseph,et al.  Addicts who survived , 1989 .